 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
|
|
|
|
Phase III
|
|
|
|
NCCTG-N0147
ECOG-N0147, N0147, NCT00079274
|
|
| |
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
|
|
|
|
Phase III
|
|
|
|
CALGB-C80405
C80405, SWOG-C80405, NCT00265850
|
|
| |
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic or Locally Advanced Colorectal Cancer or Other Solid Tumors That Cannot Be Removed by Surgery
|
|
|
|
Phase II, Phase I
|
|
|
|
CASE-1205
NCI-7325, 7325, NCT00296062
|
|
| |
Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
3C-05-3
NCT00336141
|
|
| |
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
A4061020
NCT00460603
|
|
| |
Erlotinib in Treating Patients With Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma
|
|
|
|
Phase II, Phase I
|
|
|
|
UCIRVINE-UCI06-8-01
UCI06-8-01, NCT00754494
|
|
| |
Chemotherapy Administered Every 2 Weeks with or without Pegfilgrastim (Neulasta) in Subjects with Advanced Colon Cancer
|
|
|
|
Phase II
|
|
|
|
20020715
NCT00094809
|
|
| |
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
|
|
|
|
Phase II
|
|
|
|
E7820-A001-204
NCT00309179
|
|
| |
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
|
|
|
|
Phase II
|
|
|
|
CINJ-3330
NCT00161187
|
|
| |
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
|
|
|
|
Phase II
|
|
|
|
UPCC-09205
UPCC#09205, GENENTECH-UPCC-09205, UPCC-804021, NCT00602329
|
|
